Welcome to our dedicated page for Adc Therapeutics Sa SEC filings (Ticker: ADCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ADC Therapeutics SA (NYSE: ADCT) SEC filings page brings together the company’s U.S. regulatory disclosures, offering investors structured access to its official communications. ADC Therapeutics is a commercial-stage oncology company focused on antibody drug conjugates, led by its CD19-directed therapy ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
In its recent Form 8-K filings, the company has reported preliminary revenue and cash estimates, updated clinical data from the LOTIS-7 Phase 1b trial of ZYNLONTA combinations, and the availability of corporate presentations. Other 8-Ks describe private placement agreements, unregistered sales of equity securities, and quarterly financial result announcements via attached press releases. These filings also confirm that ADC Therapeutics’ common shares trade on the New York Stock Exchange under the symbol ADCT.
Through this page, users can review filings that explain how ZYNLONTA’s accelerated and conditional approvals are being supported by confirmatory trials such as LOTIS-5 and LOTIS-7, as well as documents detailing capital-raising activities and other material events. Forms related to results of operations, material agreements, and investor presentations help clarify the company’s financial condition, clinical strategy, and risk disclosures.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points from lengthy filings, such as major clinical milestones, revenue commentary, or financing terms. Real-time updates from EDGAR, combined with simplified views of 8-Ks and other reports, allow investors researching ADCT to quickly understand what each filing means without reading every line. This makes it easier to follow ADC Therapeutics’ regulatory history, clinical progress, and corporate transactions over time.
ADC Therapeutics SA filed a resale registration allowing selling shareholders to offer up to 14,696,253 common shares from time to time as described under “Plan of Distribution.” The company is not selling any shares under this prospectus and will not receive proceeds from sales by the selling shareholders.
The filing covers shares issued in an October 2025 private placement, specifically 10,850,100 common shares and 3,846,153 common shares issuable upon exercise of pre-funded warrants. If those pre-funded warrants are exercised in cash, the company may receive up to CHF 307,692, earmarked for working capital and general corporate purposes. ADC Therapeutics’ common shares trade on the NYSE under the symbol ADCT.
ADC Therapeutics (ADCT) filed its Q3 2025 10‑Q, reporting continued operating losses alongside completed and planned capital raises. Net revenue was $16.4 million for the quarter, down from $18.5 million a year ago, driven by $15.8 million in product revenue and $0.7 million in royalties. Net loss was $41.0 million, or $0.30 per share. Cash and cash equivalents were $234.7 million at September 30, 2025.
Operating expenses were $47.4 million, including $0.4 million in restructuring costs this quarter and $13.5 million year‑to‑date tied to a June 2025 plan that reduced headcount by about 30% and initiated the UK facility shutdown. Interest expense totaled $13.4 million for the quarter. The balance sheet shows a deferred royalty obligation of $340.2 million and senior secured term loans of $115.2 million, with shareholders’ equity at a deficit of $238.2 million.
The company closed a June 2025 private placement for gross proceeds of $100.0 million (net $93.1 million) by selling 13,031,161 common shares at $3.53 and pre‑funded warrants to purchase 15,734,267 shares at $3.43. A subsequent October 2025 private placement raised $60.0 million gross (net $57.6 million) via 11,250,000 shares at $4.00 and pre‑funded warrants to purchase 3,846,153 shares at $3.90. Earlier in 2025, $5.0 million in license revenue was recognized upon Health Canada’s conditional approval of ZYNLONTA.
ADC Therapeutics SA filed an 8‑K and furnished a press release announcing financial results for the quarter ended September 30, 2025.
The release is included as Exhibit 99.1 and, as stated under Item 2.02, the information is furnished and not deemed filed under the Exchange Act.
ADC Therapeutics SA (ADCT): Oaktree-affiliated entities filed an amended Schedule 13G reporting beneficial ownership of 4.14% of ADCT’s common shares. The filing lists 4,673,441 shares beneficially owned, comprising 4,409,794 common shares and 263,647 shares issuable upon exercise of warrants. The percentage is calculated based on 112,499,395 shares outstanding as of August 1, 2025, increased by the 263,647 warrant shares.
The Oaktree reporting persons disclose shared voting and dispositive power over 4,673,441 shares and certify the securities were not acquired to change or influence control. The Brookfield-related entities named in prior filings now report 0% beneficial ownership and state they are no longer acting together with the Oaktree reporting persons for this position.
ADC Therapeutics (ADCT): RedCo II Master Fund, L.P., affiliated with Redmile Group, reported the purchase of 3,846,153 pre-funded warrants in a private placement that closed on October 27, 2025. The filing shows a transaction code P (purchase).
The purchase price per pre-funded warrant was $3.90, reflecting the common share price minus the exercise price. The warrants carry an exercise price of CHF 0.08 per share (approximately $0.10 based on the October 12, 2025 exchange rate) and are exercisable any time after closing until the tenth anniversary, subject to a 9.99% beneficial ownership blocker. Each warrant is exercisable for one common share, for a total underlying 3,846,153 common shares.
The filing notes Redmile Group, LLC and Jeremy Green may be deemed beneficial owners through management of RedCo II, with beneficial ownership disclaimed except to the extent of pecuniary interest.
ADC Therapeutics SA entered into securities purchase agreements for a $60.0 million private placement of equity to institutional investors. The Company will sell 11,250,000 common shares at $4.00 per share and pre-funded warrants to purchase 3,846,153 common shares at $3.90 per warrant. Closing is expected on October 27, 2025, subject to customary conditions.
The Company agreed to file a registration statement within 30 business days to register the resale of the common shares and the common shares issuable upon exercise of the pre-funded warrants. The pre-funded warrants are exercisable until the tenth anniversary at an exercise price of CHF 0.08 per share, include a 9.99% beneficial ownership cap (which holders may increase to 19.99% after 61 days’ notice), and permit cashless exercise under specified conditions.
ADC Therapeutics SA is registering 1,000,000 additional common shares, each with a par value of CHF 0.08, for issuance under the ADC Therapeutics SA Inducement Plan. This Form S-8 uses General Instruction E, meaning it adds to a previously registered pool of shares rather than creating a new plan from scratch.
The company incorporates by reference its latest Annual Report on Form 10-K, its two most recent Quarterly Reports on Form 10-Q, and certain Current Reports on Form 8-K, so those filings provide the detailed financial and business information for plan participants. The filing also includes legal opinions and consents, and is signed by the chief executive officer and other senior officers and directors, authorizing the registration of these additional inducement equity awards.
ADC Therapeutics SA furnished a current report to let investors know it has made an updated corporate presentation available. The presentation, dated September 30, 2025, is attached as Exhibit 99.1. The company notes that this material is being provided under Regulation FD and is not considered filed for liability purposes under the Exchange Act.
Redmile Group and affiliated entities report significant holdings in ADC Therapeutics SA. The Schedule 13G/A discloses that Redmile Group, LLC and Jeremy C. Green collectively have shared voting and dispositive power over 15,666,731 common shares, representing 14.0% of the outstanding common stock on the basis described in the filing. One affiliated fund, RedCo II Master Fund, L.P., is reported with shared power over 13,145,712 shares (11.7%). The filing states these shares are held by private investment vehicles managed by Redmile and that both Redmile Group and Mr. Green disclaim direct beneficial ownership except to the extent of any pecuniary interest. The percentage calculations use the issuer's reported outstanding shares plus a recent private placement.
ADC Therapeutics SA filed a Form S-8 on August 12, 2025 to register 4,850,000 additional common shares (par value CHF 0.08) for issuance under the ADC Therapeutics SA 2019 Equity Incentive Plan. The filing incorporates by reference prior Form S-8 registrations filed on March 15, 2023 and June 30, 2022 and references periodic reports filed in 2025.
Exhibits listed include amended and restated articles, a Swiss counsel opinion, the consent of PricewaterhouseCoopers SA, the amended plan and a filing fee table.